Bicycle Therapeutics plcBCYCNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank48
3Y CAGR-69.5%
5Y CAGR-35.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-69.5%/yr
Quarterly compound
5Y CAGR
-35.0%/yr
Recent deceleration
Percentile
P48
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 2.22% |
| Q2 2025 | 16.05% |
| Q1 2025 | -826.32% |
| Q4 2024 | 76.48% |
| Q3 2024 | 10.98% |
| Q2 2024 | 36.88% |
| Q1 2024 | -49.78% |
| Q4 2023 | -4513.46% |
| Q3 2023 | -103.01% |
| Q2 2023 | 173.47% |
| Q1 2023 | -53.13% |
| Q4 2022 | -511.99% |
| Q3 2022 | 78.18% |
| Q2 2022 | 13.18% |
| Q1 2022 | -150.55% |
| Q4 2021 | -147.66% |
| Q3 2021 | 277.02% |
| Q2 2021 | 9.75% |
| Q1 2021 | 17.51% |
| Q4 2020 | -66.42% |
| Q3 2020 | 19.14% |
| Q2 2020 | -158.85% |
| Q1 2020 | 519.29% |
| Q4 2019 | 54.02% |
| Q3 2019 | -43.07% |
| Q2 2019 | -46.28% |
| Q1 2019 | 41.26% |
| Q4 2018 | -90.08% |
| Q3 2018 | 12.00% |
| Q2 2018 | 27.22% |
| Q1 2018 | -432.43% |
| Q4 2017 | 0.00% |